Instructions for Authors 2019

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Open Access Policy. IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 600.00 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Ethical Policies and Standards. IN VIVO agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html
In case a submission is incomplete, the corresponding Author will be notified accordingly.
Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfills the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

5. Authors should pay attention to the following points when writing an article for IN VIVO:

- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
- Results given in figures should not be repeated in tables.
- Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section.
- Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
- The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

8. Articles submitted to IN VIVO may be rejected without review if:

- they do not fall within the journal’s policy.
- they do not follow the instructions for authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to IV.
- plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 59%).

9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org.

11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).
Selection of Recent Articles

Adipose-specific Monocyte Chemotactic Protein-1 Deficiency Reduces Pulmonary Metastasis of Lewis Lung Carcinoma in Mice. S. SUNDARAM, L. YAN (Grand Forks, ND, USA)

The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. J. OSMAN, K. BELLAMKONDA, Q. LIU, T. ANDERSSON, A. SJÖLANDER (Malmö, Sweden)


Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus. J.-B. LIU, C. YUE, D. CHEN, W. CHEN, T.-T. BAO, H.-X. LIU, Y. CAO, W.-B LI, T. JIAN, Z. YANG, R.M. HOFFMAN, C. YU (Zhengzhou; Nanjing, PR China; San Diego, CA, USA)

The Rectus Sheath Block (RSB) Analgesia Could Enhance Significantly the Patient Satisfaction Following Midline Laparotomy in Benign Disease and in Cancer: A Prospective Study With Special Reference to Nitrosative Stress Marker Nitrotyrosine (NT) Plasma Concentrations. V. KUOSMANEN, I. SAIMANEN, D. RAHKOLA, J. KÄRKÄINEN, T. SELANDER, M. PURDY, H. KOKKI, M. KOEKINEN (Kuopio, Finland)

9 Basic Gene Expression Characteristics of Glioma Stem Cells and Human Glioblastoma. D. SAKAMOTO, T. TAKAGI, M. FUJITA, S. OMURA, Y. YOSHIDA, T. IDA, S. YOSHIMURA (Hyogo; Osaka, Japan)

Patterns of Care in Pediatric Cranioopharyngioma: Outcomes Following Definitive Radiotherapy. T.K. HILL, M.J. BAIN, V. VERMA, M. ALAM, E.R. LYDEN, C. LIN, E.P. CONNOLLY, C. ZHANG (Omaha, NE; Pittsburgh, PA; New York, NY, USA)

HPV Status and Survival in Non-Oropharyngeal Squamous Cell Carcinoma of the Head and Neck. V.B. WOOKEY, A.K. APPiah, A. KALLAM, V. ERNANI, L.M. SMITH, A.K. GANTI (Omaha, NE, USA)


Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. D. WAKITA, T. IWAI, S. HARADA, M. SUZUKI, K. YAMAMOTO, M. SUGIMOTO (Kanagawa, Japan)

Targeted and Efficient Delivery of siRNA Using Tunable Polymeric Hybrid Micelles for Tumor Therapy. F. HAO, S. DONG, C. YANG, Z. LI, Z. CHENG, L. ZHONG, L. TENG, Q. MENG, J. LU, F. WU, J. XIE, L. TENG, R.J. LEE (Changchun, PR China; Des Moines, IA; Columbus, OH, USA)
General Policy

- CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.

- CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online only and open access with Stanford University HighWire Press. For more information please visit our website www.cgp.iiarjournals.org.

- Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

- U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

- E-mail: journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors. K. SATO, A. NIIDA, T. MASUDA, D. SHIMIZU, T. TOBO, Y. KURODA, H. EGUCHI, T. NAKAGAWA, Y. SUZUKI, K. MIMORI (Oita; Fukuoka; Tokyo; Chiba, Japan)

MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer. U.H. WEIDLE, F. BIRZELE, A. NOPORA (Penzberg, Germany; Basel, Switzerland)

Three Poliovirus Sequences in the Human Genome Associated With Colorectal Cancer. S. LEHRER, P.H. RHEINSTEIN (New York, NY, USA)

mRNA Expression of CDK2AP1 in Human Breast Cancer: Correlation with Clinical and Pathological Parameters. R. GERA, L. MOKBEL, W.G. JIANG, K. MOKBEL (London; Cardiff, UK)

Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality. S. TORKILDSEN, L.GORUNOVA, S. HEIM, G.E. TJØNNFJORD, S. SPETALEN, B. RISBERG, H.T.T. TRAN, I. PANAGOPoulos (Oslo; Lørenskog, Norway)

Isoforms of Ionotropic Glutamate Receptor GRK2 Induce Senescence of Carcinoma Cells. V.K. ZHAWAR, R.P. KANDPAL, R.S. ATHWAL (Philadelphia, PA; Pomona, CA, USA)

Human Periprostatic Adipose Tissue: Secretome from Patients With Prostate Cancer or Benign Prostate Hyperplasia. P.A. SACCA, O.N. MAZZA, C. SCORTICATI, G. VITAGLIANO, G. CASAS, J.C. CALVO (Buenos Aires, Argentina)

MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 via PAX3. R. FUJII, E. OSAKA, K. SATO, Y. TOKUHASHI (Tokyo, Japan)

NOTUM Is Involved in the Progression of Colorectal Cancer. J.H. YOON, D. KIM, J. KIM, H. LEE, J. GHIM, B.J. KANG, P. SONG, S.H. RYU, T.G. LEE (Daegu; Pohang, Republic of Korea)

The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. U.H. WEIDLE, A. EPP, F. BIRZELE, U. BRINKMANN (Penzberg, Germany; Basel, Switzerland)


Malnutrition and Survival – Bioimpedance Data in Head Neck Cancer Patients. J. BÜNTZEL, O. MICKE, K. KISTERS, J. BÜNTZEL, R. MÜCKE (Göttingen; Bielefeld; Nordhausen, Germany) ............
Effectiveness of Synthetic Polymer-coated Peripherally Inserted Central Catheter in Patients With Advanced Cancer. Y. TAKEZAWA, K. IZUMI, T. KAMIJIMA, K. MACHIYOKA, T. SHIMA, H. IWAMOTO, T. NOHARA, K. SHIGEHARA, Y. KADONO, C. SETO, A. MIZOKAMI (Toyama; Kanazawa, Japan) ............................................................... 877

Effectiveness of a 12-month Exercise Intervention on Physical Activity and Quality of Life of Breast Cancer Survivors; Five-Year Results of the BREX-study. H. PENTTINEN, M. UTRIAINEN, P.-L. KELLOKUMPU-LEHTINEN, J. RAITANEN, H. SIEVÄNEN, R.NIKANDER, C. BLOMQVIST, R. HUOVINEN, L. VEHMANEN, T. SAARTO (Helsinki; Tampere; Turku, Finland) ............................................................. 881

Prognostic Value of Serum Tumor Markers in Patients With Stage III NSCLC Treated With Chemoradiotherapy. T. TOKITO, K. AZUMA, K. YAMADA, Y. NAITO, N. MATSUO, H. ISHII, H. NATORI, T. KINOSHITA, T. HOSHINO (Kurume, Japan) ............................................................. 889

Early Second Round Targeted Biopsy of PI-RADS Score 3 or 4 in 256 Men With Persistent Suspicion of Prostate Cancer. P. PEPE, A. GARUFI, G.D. PRILO, M. PENNISI, F. FRAGGETTA (Catania, Italy) ............................................................. 897

Does Decision-making in End-of-life Care Differ Between Graduating Medical Students and Experienced Physicians? A. ALMINOJA, R.P. PIILI, H. HINKKA, R. METSANOJA, O. HIRVONEN, K. TYYNELÄ-KORHONEN, J. KALEVA-KEROLA, T. SAARTO, P.-L. KELLOKUMPU-LEHTINEN, J.T. LEHTO (Tampere; Kangasala; Turku; Kuopio; Helsinki, Finland) .................................................................................. 903


Impact of MDM2, TP53 and P14ARF Polymorphisms on Endometrial Cancer Risk and Onset. W. WUJCICKA, A. ZAJC, G. STACHOWIAK (Lodz, Poland) .............................................................................................................................. 917

Definitive Radiotherapy for Older Patients Aged \( \geq 75 \) Years With Localized Esophageal Cancer. G. SUZUKI, H. YAMAZAKI, N. AIBE, K. MASUI, T. KIMOTO, D. SHIMIZU, T. NISHIMURA, A. NAKASHIMA, K. MACHIDA, K. KAWABATA, Y. OTA, H. FUJIWARA, T. ISHIKAWA, K. YAMADA (Kyoto, Japan) .............................................................................................................................................. 925

A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer. K. SHITARA, Y. YODO, S. IINO (Chiba; Osaka, Japan) .............................................................................................................................................. 933

Invasion of Adjacent Lumbar Vertebral Body from Renal Pelvis Carcinoma: Associated With Bone Metastasis but Easily Overlooked on Initial CT Scan. T.-Y. LIAO, C.-C. LIAW, K.-H. TSUI, Y.-H. JUAN (Taoyuan, Taiwan, ROC) .................................................................................................................................................. 939


Combined Chemoradiotherapy-induced Weight Loss Decreases Survival in Locally Advanced Non-small Cell Lung Cancer Patients. Y.-J. KIM, C. SONG, K.-Y. EOM, I.A. KIM, J.-S. KIM (Seongnam-si; Seoul, Republic of Korea) ............................................................................................................................................ 955

Contents continued on the preceding page
Fistein Suppresses Human Osteosarcoma U-2 OS Cell Migration and Invasion via Affecting FAK, uPA and NF-κB Signaling Pathway In Vitro. J.-K. CHEN, S.-F. PENG, K.C. LAI, H.-C. LIU, Y.-P. HUANG, C.-C. LIN, A.-C. HUANG, F.-S. CHUEH, J.-G. CHUNG (Changhua; Taichung; Tainan; Yunlin; Yilan, Taiwan, ROC).......................... 801


Combined EGFR/ALK Expression Analysis in Laryngeal Squamous Cell Carcinoma. A. POLITI, E. TSIAMBAS, N.S. MASTRONIKOLIS, D. PESCHOS, I. ASPROUDIS, E. KYRIS, I.E. ARMATA, A. CHRYSOVERGIS, A. ASIMAKOPOULOS, V.S. PAPANIKOLAOU, A. BATISTATOU, V. RAGOS (Ioannina; Athens; Patras, Greece; Cambridge, UK; Luxembourg, Luxembourg) ......................................................... 815


Clinical Studies

Reconstruction of Spinal Soft Tissue Defects With Perforator Flaps From the Paraspinal Region. P.G. DI SUMMA, R.D. LARGO, T. ISMAIL, M. TREMP, A. LUNGER, R. WETTSTEIN, S.M. KRÄHENBUHL, S. GIORDANO, D.J. SCHAFFER, S. SCHAEREN, D.F. KALBERMATTEN (Lausanne; Basel, Switzerland; Turku, Finland) .................................................................................... 827


Three-dimensional Assessment of the Breast: Validation of a Novel, Simple and Inexpensive Scanning Process. C.M. ORANGES, S. MADDURI, P. BRANTNER, B. MSALLEM, S. GIORDANO, B. BENITEZ, D.F. KALBERMATTEN, D.J. SCHAFFER, F.M. THIERINGER (Basel; Allschwil, Switzerland; Turku, Finland) ..................................................................................... 839

Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study. T. OKADA, T. SAOTOME, T. NAGAO, T. MASUBUCHI, C. FUSHIMA, T. MATSUKI, H. TAKAHASHI, K. MIURA, K. TSUKAHARA, Y. TADA (Tokyo; Chiba, Japan) ........................................................................ 843


Efficacy and Safety of Imatinib in Paediatric CML – A Single Centre Study. C. SMEDING, A. SZYDŁO, K. PIELUSZCZAK, K. GRZESZKIEWICZ, K. PAWELEC (Warsaw, Poland) ........................................................................................................ 869

Contents continued on the preceding page

Pedicle Periosteum as a Barrier for Guided Bone Regeneration in the Rabbit Frontal Bone. A. HASUIKE, H. UJIIE, M. SENOO, M. FURUHATA, M. KISHIDA, H. AKUTAGAWA, S. SATO (Tokyo, Japan) .......... 717

The Influence of Haemostatic Dressing Prototypes for the Emergency Services on the Histopathological Parameters of Porcine Muscle. P. HOLAK, Z. ADAMIAK, I. BABINSKA, M. JALYNSKI, P. JASTRZEBSKI, L. GRABARCZYK, M. BRZEZINSKI, J. BORYS, A. TOBOLSKA, J. GLODEK (Olsztyń; Gdańsk; Białystok, Poland) .................................................................................................................... 723

DNA Adduct Assessment During Antihormonal Treatment of Perianal Gland Tumors With Tamoxifen in Male Dogs. A. BRODZKI, M.R. TATARA, P. BRODZKI, I. BALICKI (Lublin, Poland).................................................................................................................. 731


Mast Cells as an Indicator and Prognostic Marker in Molecular Subtypes of Breast Cancer. E. CARPENCO, R.A. CEAUȘU, A.M. CIMPEAN, P.N. GAJE, L. ŞAPTEFRAŢI, V. FULGA, V. DAVID, M. RAICA (Chișinău, Republic of Moldova; Timișoara, Romania) .................................................................................................................. 743


Efficacy of Ozone and Selenium Therapy for Alcoholic Liver Injury: An Experimental Model. Y. ADALI, H.A. EROĞLU, M. MAKAV, G.F. GUOVPEN (Hanakkale; Kars; Rize, Turkey) .................................................................................................................. 763

Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue. E. SIERKO, E. ZABROCKA, K. OSTROWSKA-CICHOCKA, P. TOKAJUK, L. ZIMNOCH, M.Z. WOJTUKIEWICZ (Bialystok, Poland; Stony Brook, NY, USA).................................................................................................................. 771


Characteristics of Coronary Artery Disease Patients Who Have a Polymorphism in the Cholesterol Ester Transfer Protein (CETP) Gene. G.D. ARIKAN, S. ISBIR, S.G. YILMAZ, T. ISBIR (Istanbul, Turkey) ... 787

CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma. C.-H. HONG, S.-H. LIN, C.-H. LEE (Kaohsiung; Taipei, Taiwan, ROC).................................................................................................................. 793

Contents continued on the preceding page